A detailed history of Godsey & Gibb Associates transactions in Eli Lilly & CO stock. As of the latest transaction made, Godsey & Gibb Associates holds 1,192 shares of LLY stock, worth $1.08 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
1,192
Previous 1,192 -0.0%
Holding current value
$1.08 Million
Previous $1.08 Million 2.13%
% of portfolio
0.1%
Previous 0.11%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 23, 2024

SELL
$724.87 - $909.04 $10,873 - $13,635
-15 Reduced 1.24%
1,192 $1.08 Million
Q3 2023

Oct 25, 2023

SELL
$434.7 - $599.3 $6,520 - $8,989
-15 Reduced 1.23%
1,207 $648,000
Q2 2023

Jul 25, 2023

SELL
$350.74 - $468.98 $18,589 - $24,855
-53 Reduced 4.16%
1,222 $573,000
Q1 2023

Apr 18, 2023

SELL
$310.63 - $364.82 $31,063 - $36,482
-100 Reduced 7.27%
1,275 $437,000
Q4 2022

Jan 18, 2023

BUY
$321.55 - $374.67 $442,131 - $515,171
1,375 New
1,375 $0
Q1 2022

Apr 28, 2022

SELL
$234.69 - $291.66 $299,229 - $371,866
-1,275 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$221.6 - $272.71 $282,540 - $347,705
1,275 New
1,275 $295,000
Q2 2021

Aug 05, 2021

SELL
$180.55 - $233.54 $248,256 - $321,117
-1,375 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$164.32 - $212.72 $41,244 - $53,392
-251 Reduced 15.44%
1,375 $257,000
Q4 2020

Feb 12, 2021

SELL
$130.46 - $172.63 $38,485 - $50,925
-295 Reduced 15.36%
1,626 $275,000
Q3 2020

Nov 10, 2020

SELL
$146.22 - $169.13 $731 - $845
-5 Reduced 0.26%
1,921 $284,000
Q2 2020

Aug 12, 2020

BUY
$136.42 - $164.18 $682 - $820
5 Added 0.26%
1,926 $316,000
Q1 2020

May 11, 2020

SELL
$119.05 - $147.35 $2,976 - $3,683
-25 Reduced 1.28%
1,921 $266,000
Q3 2019

Nov 13, 2019

BUY
$106.79 - $116.16 $207,813 - $226,047
1,946 New
1,946 $218,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $864B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Godsey & Gibb Associates Portfolio

Follow Godsey & Gibb Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Godsey & Gibb Associates, based on Form 13F filings with the SEC.

News

Stay updated on Godsey & Gibb Associates with notifications on news.